Pfizer Completes Acquisition of Two GSK Vaccines
Pfizer has completed the acquisition of GlaxoSmithKline's quadrivalent meningococcal ACWY vaccines, Nimenrix and Mencevax.
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) is a single-dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease. It is indicated for all age groups above one year of age. Launched three years ago, Nimenrix is currently registered and approved for sale in 63 countries across the European Economic Area (EEA 30), Canada, Australia, and emerging markets, with registrations under review in another 17 countries across Africa, Asia, Eastern Europe, and the Middle East.
Mencevax (meningococcal polysaccharide serogroups A, C, Y and W-135 vaccine) is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers in countries where the disease is endemic or highly epidemic. Mencevax is indicated for use across all age groups from two years of age and is currently registered and approved in 78 countries across Africa, Asia, Australia, Europe, Latin America, Middle East, and New Zealand.